Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4502

Sort by

Sort Order Select

Journal Articles

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Shirong Li, Jing Fu, Jun Yang, Huihui Ma, Divaya Bhutani, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch

Blood (2021) 137 (13): 1754–1764.

https://doi.org/10.1182/blood.2020006334

Published: 2021

Includes: Supplemental data

Journal Articles

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4402.

https://doi.org/10.1182/blood-2019-130888

Published: 2019

Journal Articles

Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma

Yan Song, PhD, Ting DU, PhD, Arghya Ray, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 4403.

https://doi.org/10.1182/blood-2019-122952

Published: 2019

Journal Articles

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

Panagiotis Efentakis, PhD, Ioanna Andreadou, PhD, Panagiota-Efstathia Nikolaou, PhD, Claudius Witzler, Svenja Siemer, Eftathios Kastritis, Philip Wenzel, MD PhD, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 3797.

https://doi.org/10.1182/blood-2019-123522

Published: 2019

Journal Articles

The Splenic Microenvironment Is a Novel Site of Relapse Following ABT-199 Treatment

Alessandra Di Grande, BSc, Sofie Piers, Pieter Van Vlierberghe, PhD, Triona Ni Chonghaile, PhD BSc

Blood (2019) 134 (Supplement_1): 3800.

https://doi.org/10.1182/blood-2019-127970

Published: 2019

Journal Articles

Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Alexandra Niedermayer, MSc, Stefanie Enzenmüller, PhD, Eugen Tausch, Stephan Stilgenbauer, MD, Felix Seyfried, MD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD

Blood (2019) 134 (Supplement_1): 3954.

https://doi.org/10.1182/blood-2019-126582

Published: 2019

Journal Articles

Heme Oxygenase-1 in Leukemia Cells Promotes Cancer Associated Fibroblasts Mediating Progression of Acute Lymphoblastic Leukemia

Chengyun Pan, Dan Ma, MD, Qin Fang, Ping Liu, Jishi Wang, PhD

Blood (2019) 134 (Supplement_1): 3958.

https://doi.org/10.1182/blood-2019-130440

Published: 2019

Journal Articles

CRISPR-Cas9 Screen Identifies XPO7 As a Potential Therapeutic Target for TP53 -Mutated AML

Yuichiro Semba, MD PhD, Takuji Yamauchi, MD PhD, Fumihiko Nakao, MD, Jumpei Nogami, PhD, Matthew C. Canver, MD PhD, Luca Pinello, PhD, Daniel E. Bauer, MD PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 3784.

https://doi.org/10.1182/blood-2019-129623

Published: 2019

Journal Articles

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Nadia El Khawanky, Bsc(Biomed), BHlthSc(Hons), Amy Hughes, PhD, Wenbo Yu, PhD, Sanaz Taromi, PhD, Jade Clarson, BSc, Angel F. Lopez, MD PhD, Michael P. Brown, MD PhD, Justus Duyster, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Deborah L. White, PhD FFSc (RCPA), Agnes S. M. Yong, MD PhD, Robert Zeiser, MD

Blood (2019) 134 (Supplement_1): 3904.

https://doi.org/10.1182/blood-2019-124684

Published: 2019

Journal Articles

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Christoph Kornauth, Charles Herbaux, MD MSc, Bernd Boidol, PhD, Chantal Guillemette, Patrick Caron, Stéphanie Poulain, MD PhD, Olivier Tournilhac, Marius E Mayerhoefer, Ulrich Jaeger, MD, Stefan Kubicek, Matthew S. Davids, MD, Philipp Bernhard Staber, MD PhD

Blood (2019) 134 (Supplement_1): 3965.

https://doi.org/10.1182/blood-2019-124392

Published: 2019

Journal Articles

Loss of Asxl1 Cooperates with Oncogenic Nras to Drive CMML Progression

Xiaona You, PhD, Zhi Wen, PhD, Guangyao Kong, Adhithi Rajagopalan, BS, Erik A. Ranheim, MD PhD, Yun Zhou, MS, Mrinal M Patnaik, MDMBBS, Jing Zhang, PhD

Blood (2019) 134 (Supplement_1): 3790.

https://doi.org/10.1182/blood-2019-131347

Published: 2019

Journal Articles

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Wittawat Chantkran, MD MSc, Daniella Zheleva, PhD, Sheelagh Frame, PhD, Ya-Ching Hsieh, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 3938.

https://doi.org/10.1182/blood-2019-124072

Published: 2019

Journal Articles

Targeting Salt-Inducible Kinase 3 As a Therapeutic Approach for Acute Myeloid Leukemia

Shan Lin, Yusuke Tarumoto, Jinhua Wang, PhD, Joseph Milazzo, Yali Xu, Nathanael Gray, Christopher Vakoc, Kimberly Stegmaier, MD

Blood (2019) 134 (Supplement_1): 3941.

https://doi.org/10.1182/blood-2019-125278

Published: 2019

Journal Articles

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

Laura Monaghan, BSc, Matthew Edward Massett, MSc, BSc, Roderick P Bunschoten, BSc, Petrisor Alin Pirvan, MSc, BSc, Alex Hoose, Bsc, PhD, Taeju Park, BSc, Joana Bittencourt-Silvestre, BSc, MSc, Robert M J Liskamp, BSc, PhD, Heather G Jørgensen, Xu Huang, BSc, PhD

Blood (2019) 134 (Supplement_1): 3756.

https://doi.org/10.1182/blood-2019-125355

Published: 2019

Journal Articles

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

Jaesung Seo, PhD, Li Li, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 3759.

https://doi.org/10.1182/blood-2019-130339

Published: 2019

Journal Articles

PBX1 Co-Operates with FOXM1 to Regulate Myeloma Cell Proliferation and to Define an Ultra High-Risk chr1q Gain Myeloma Patient Subgroup

Nikolaos Trasanidis, Alexia Katsarou, Bien Bergonia, Keren Keren, Ioannis V. Kostopoulos, Kanagaraju Ponnusamy, Reema Paudel, Xiaolin Xiao, Holger W Auner, MD PhD, Irene Roberts, Kikkeri Naresh, MD, Aristeidis Chaidos, Luca Magnani, Valentina S Caputo, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 3760.

https://doi.org/10.1182/blood-2019-124109

Published: 2019

Journal Articles

Therapeutic Stratification of PTEN-MYC Axis Appears to be Promising for Molecular Targeted Therapies in Refractory and Relapsed T-Cell Acute Lymphoblastic Leukemia

Heinz Ahlert, MSc, BSc, Sanil Bhatia, PhD, Marc Remke, MD, Melf Sönnichsen, M.Sc., Niklas Dienstbier, M.Sc., Ute Fischer, PhD, Julia Hauer, MD, Arndt Borkhardt, MD

Blood (2019) 134 (Supplement_1): 3883.

https://doi.org/10.1182/blood-2019-128136

Published: 2019

Journal Articles

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Shelby Sloan, BS, Fiona Brown, BS, JI Hyun Chung, PhD, Alexander Prouty, BS, Esther Wheeler, BS, Bonnie K Harrington, DVM, PhD, Eric Brooks, BS, Ayse S Yilmaz, MS, Hatice G Ozer, PhD, John C. Byrd, MD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Rosa Lapalombella, PhD, Kris Vaddi, PhD, Peggy Scherle, PhD, Youssef Youssef, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD

Blood (2019) 134 (Supplement_1): 4065.

https://doi.org/10.1182/blood-2019-128998

Published: 2019

Journal Articles

Targeting eIF4A Using MZ-735 Potently Induces Cell Death in Lymphoma Cells and Rapidly Represses mRNA Translation at the Global Level and in C-MYC and Other Oncogenes

Ipsita Pal, PhD, Yu Ri Kim, MD, Sohani Das Sharma, PhD, Prabhjot S. Mundi, MD, Andre M. Grilo, PhD, Luke E Berchowitz, PhD, Mingzhao Zhu, PhD, Hull G. Kenneth, PhD, Daniel Romo, PhD, Owen O'Connor, MD PhD, Marko Jovanovic, PhD, Changchun Deng, MD PhD

Blood (2019) 134 (Supplement_1): 4067.

https://doi.org/10.1182/blood-2019-131816

Published: 2019

Journal Articles

Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics

Artavazd Arumov, BSc, Piumi Y. Liyanage, BS, Asaad Trabolsi, MD, Lingxiao Li, PhD, Evan R. Roberts, BS, Daniel Bilbao, PhD, Roger M. LeBlanc, PhD, Jonathan H. Schatz, MD

Blood (2019) 134 (Supplement_1): 4061.

https://doi.org/10.1182/blood-2019-122599

Published: 2019

NARROW

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

The Splenic Microenvironment Is a Novel Site of Relapse Following ABT-199 Treatment

Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Heme Oxygenase-1 in Leukemia Cells Promotes Cancer Associated Fibroblasts Mediating Progression of Acute Lymphoblastic Leukemia

CRISPR-Cas9 Screen Identifies XPO7 As a Potential Therapeutic Target for TP53 -Mutated AML

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Loss of Asxl1 Cooperates with Oncogenic Nras to Drive CMML Progression

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Targeting Salt-Inducible Kinase 3 As a Therapeutic Approach for Acute Myeloid Leukemia

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

Dissociation of the DNMT3A-HDAC1 Repressor Complex Induces PD-L1 Expression

PBX1 Co-Operates with FOXM1 to Regulate Myeloma Cell Proliferation and to Define an Ultra High-Risk chr1q Gain Myeloma Patient Subgroup

Therapeutic Stratification of PTEN-MYC Axis Appears to be Promising for Molecular Targeted Therapies in Refractory and Relapsed T-Cell Acute Lymphoblastic Leukemia

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Targeting eIF4A Using MZ-735 Potently Induces Cell Death in Lymphoma Cells and Rapidly Represses mRNA Translation at the Global Level and in C-MYC and Other Oncogenes

Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only